Tiziana Life Sciences Partners with Saudi Institutions for MS Trial

Key Facts

1Tiziana Life Sciences signed a Memorandum of Understanding with King Abdullah International Medical Research Center (KAIMRC) and the Foundation for Neurologic Diseases.

2The study will focus on using intranasal foralumab in combination with anti-CD20 therapy for relapsing-remitting multiple sclerosis patients.

In a move reflecting the strategic expansion of global biotech firms into the Saudi market, Tiziana Life Sciences has signed a Memorandum of Understanding with the King Abdullah International Medical Research Center (KAIMRC) and the Foundation for Neurologic Diseases. The study will focus on using intranasal foralumab in combination with anti-CD20 therapy for relapsing-remitting multiple sclerosis patients. This trial aims to address neuroinflammation in patients who do not respond adequately to standard therapies alone.

This collaboration aligns with Saudi Arabia's National Biotechnology Strategy and was formalized during the Riyadh Global Medical Biotechnology Summit. Per market data, TLSA shares closed at $0.7701 on September 16, 2026, having reached a day high of $0.88. This partnership represents an additional indication for the company's pipeline, which includes ongoing programs for non-active secondary progressive MS.

Investors should watch TLSA price levels, which stood at $0.7701 (close September 16, 2026), as the partnership progresses from the MOU stage. According to the economic calendar, recent global sentiment has been shaped by US inflation data released on September 11, which impacts risk appetite in the biotech sector. Future clinical trial results remain the primary catalyst for the company's valuation moving forward.